Last updated: July 22, 2026
Litigation summary and analysis for Gilead Sciences, Inc. v. Mylan Inc. (1:15-cv-00149)
Executive summary: The available docket text for Gilead Sciences, Inc. v. Mylan Inc., 1:15-cv-00149 does not provide the case caption details (drug/Orange Book patent list), asserted patents, claim constructions, claim-for-relief framing, or final disposition sufficient to produce a complete, accurate litigation summary tied to a specific infringement theory and exclusivity or Paragraph IV posture.
What is the case background for Gilead v. Mylan 1:15-cv-00149?
Featured snippet answer: Insufficient docket content is available in the provided material to confirm the underlying product, asserted patents, or procedural posture for 1:15-cv-00149.
Which drug and Orange Book patents are at issue?
No drug name, NDA/BLA number, Orange Book listing, or patent numbers appear in the provided prompt. Without those identifiers, the litigation cannot be mapped to a specific regulatory event (Paragraph IV vs. non-Paragraph IV) or tied to specific patent estate coverage.
What triggers the suit: Paragraph IV, patent infringement, or declaratory judgment?
The prompt includes only the parties and case number, not the complaint’s factual allegations. That prevents classification of the case into a definable Hatch-Waxman pathway and prevents a credible chronology of exclusivity or generic launch risk.
What patents does Gilead assert against Mylan in 1:15-cv-00149?
Featured snippet answer: The asserted patent list is not present in the provided material.
Are the asserted patents composition, formulation, method-of-use, or manufacturing?
No patent categories or numbering are provided. Without patent numbers and titles, there is no way to analyze likely claim scope, enforceability posture (subject matter eligibility, obviousness, written description), or infringement strength.
Does the case target formulation patents or process patents?
No formulation/process identifiers are included in the provided prompt. Any attempt to infer formulation or manufacturing claims would be speculative and would not meet the completeness requirement.
What are the key litigation events and timeline in 1:15-cv-00149?
Featured snippet answer: The procedural record (motions, orders, trial status, settlement dates, and final judgment) is not present in the provided material.
Motion practice that typically drives outcomes in Hatch-Waxman cases
The prompt does not supply any entries such as:
- preliminary injunction / TRO motions
- dismissal motions under Rule 12
- claim construction orders (Markman)
- summary judgment
- Daubert or expert rulings
Without docket entries, a timeline cannot be assembled.
Final outcome: dismissal, settlement, injunction, or judgment?
No disposition is provided. A reliable analysis requires knowing whether the case ended by:
- final judgment after trial
- consent judgment
- dismissal with prejudice
- settlement with stipulated final order
- non-infringement or invalidity rulings
None of these data points appear in the prompt.
How strong is Gilead’s infringement case and Mylan’s defenses in 1:15-cv-00149?
Featured snippet answer: The litigation merits cannot be assessed because the asserted claims, claim constructions, and invalidity/infringement contentions are not included.
Infringement analysis: product-by-product and claim-by-claim mapping
No FDA product attributes, ANDA composition, dosage form, or process parameters are provided. Claim-by-claim mapping requires:
- asserted independent claims
- representative claim language
- technical disclosure from accused labels and formulations
None is present.
Invalidity and unenforceability defenses
No invalidity theories (35 USC §101, §102, §103, §112) or inequitable conduct allegations are included. Without the defense content, strength cannot be evaluated on:
- anticipation/obviousness references
- enablement and written description
- prosecution history estoppel
- expert rebuttals
Did the case involve a Paragraph IV certification or biosimilar-style risk?
Featured snippet answer: The regulatory trigger and certification type are not stated.
Hatch-Waxman exclusivity and 30/180-day exclusivity impacts
No Orange Book listing, 30-month stay, or exclusivity status is provided. Without that, there is no defensible analysis of:
- when an ANDA could launch
- whether a 30-month stay applied
- whether another first-filer impacted exclusivity
Biosimilar vs. generic pathway
The prompt does not state whether the asserted product is small molecule (ANDA) or biologic (BLA). No biosimilar framework applies without biologics identifiers.
What does this litigation mean for generic entry risk for Mylan?
Featured snippet answer: Generic entry risk cannot be calculated without (1) asserted patent expiry dates, (2) settlement terms or court-imposed launch dates, and (3) Orange Book listing status.
When could Mylan launch absent a settlement or injunction?
No asserted patent expiration or effective blocking patents are provided. Launch risk depends on:
- earliest expiring asserted patent
- any injunction or stay duration
- settlement “carve-outs” and design-around provisions
None are available.
What manufacturing or IP barriers could block entry?
No claim type (composition vs. process) or accused design is provided. Barriers like:
- process patent restrictions
- composition equivalence constraints
- formulation bioequivalence carve-outs
cannot be analyzed without the technical and claim details.
How does the 1:15-cv-00149 case compare with other Gilead v. generic manufacturers?
Featured snippet answer: No comparative analysis can be executed because the prompt provides no drug or patent estate context for this case.
Shared asserted patents across Gilead generic disputes
Gilead frequently asserts patent families across multiple generic defendants. Comparison requires:
- the asserted patent numbers
- common specification families
- recurring claim constructions
None are provided.
Differences in outcomes across defendants
Outcome comparisons require docket dispositions or settlement announcements with dates and scope. The prompt includes none.
What settlement or licensing terms were reached in 1:15-cv-00149?
Featured snippet answer: Settlement/licensing terms are not present in the provided material.
Were there any “no-AT-risk” agreements or stipulated injunctions?
No settlement instrument or court order language is provided. That prevents analysis of:
- launch-forcing provisions
- payment-for-delay or related constraints
- stipulations about infringement/noninfringement
What carve-outs existed for dosage strength or delivery form?
No product strengths, dosage forms, or label limitations are provided.
What is the Orange Book status of the relevant patents?
Featured snippet answer: The Orange Book listings for this case are not specified in the prompt.
Which patents are listed as method-of-use vs. product patents?
No Orange Book patent numbers are stated. This blocks analysis of:
- listed patent type and statutory basis
- whether they are “listed in connection with” the NDA
- implications for FDA approval timing
Key takeaways
- The provided prompt contains insufficient docket and patent-specific information to produce a complete litigation summary and merits analysis for Gilead Sciences, Inc. v. Mylan Inc., 1:15-cv-00149.
- Without the drug/NDA, asserted patent numbers, and disposition timeline, any infringement strength, defense posture, settlement scope, or generic launch-risk analysis would not be accurate.
FAQs
- What is the asserted drug and NDA number in Gilead v. Mylan 1:15-cv-00149?
- Which Orange Book patents does Gilead list as the basis of the lawsuit?
- Did the case end in a settlement, dismissal, or final judgment?
- What launch date constraints (if any) did the court or settlement impose on Mylan?
- Did the litigation include claim construction (Markman) or summary judgment rulings affecting infringement scope?
References
- Federal court case docket for Gilead Sciences, Inc. v. Mylan Inc., No. 1:15-cv-00149.
